APO Research
Talk to an analyst

APO RESEARCH · REPORT

C Difficile Infection Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global C Difficile Infection Drug Industry Growth and Trends Forecast to 2032

22 December 2025110 pages

Choose your research edition.

Industry ResearchC Difficile Infection Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal C Difficile Infection Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal C Difficile Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C Difficile Infection Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal C Difficile Infection Drug Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global C Difficile Infection Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for C Difficile Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for C Difficile Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for C Difficile Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of C Difficile Infection Drug include Zhejiang Medicine, Sanofi, Merck, Eli Lilly, Pfizer, Fresenius, AstraZeneca, Xellia and Strides, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global C Difficile Infection Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The C Difficile Infection Drug market size, estimates, and forecasts are presented in terms of sales volume (k tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global C Difficile Infection Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to C Difficile Infection Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global C Difficile Infection Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

C Difficile Infection Drug Market by Company

Zhejiang Medicine

Sanofi

Merck

Eli Lilly

Pfizer

Fresenius

AstraZeneca

Xellia

Strides

Merus labs

Lupin

Flynn Pharma

Astellas

Aspen Pharmacare

ANI Pharmaceutical

Akorn

C Difficile Infection Drug Segment by Type

Fidaxomycin

Metronidazole

Vancomycin

Others

C Difficile Infection Drug Segment by Application

Pre-treatment

Mid-term treatment

Others

C Difficile Infection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C Difficile Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C Difficile Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C Difficile Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of C Difficile Infection Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of C Difficile Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Fidaxomycin Table 2. Major Company of Metronidazole Table 3. Major Company of Vancomycin Table 4. Major Company of Others Table 5. Global C Difficile Infection Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global C Difficile Infection Drug Sales by Type (2021-2026) & (k tons) Table 7. Global C Difficile Infection Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global C Difficile Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global C Difficile Infection Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global C Difficile Infection Drug Price by Type (2021-2026) & (US$/ton) Table 11. Global C Difficile Infection Drug Sales by Type (2027-2032) & (k tons) Table 12. Global C Difficile Infection Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global C Difficile Infection Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global C Difficile Infection Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global C Difficile Infection Drug Price by Type (2027-2032) & (US$/ton) Table 16. North America C Difficile Infection Drug Sales by Type (2021-2026) & (k tons) Table 17. North America C Difficile Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe C Difficile Infection Drug Sales by Type (2021-2026) & (k tons) Table 19. Europe C Difficile Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific C Difficile Infection Drug Sales by Type (2021-2026) & (k tons) Table 21. Asia-Pacific C Difficile Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America C Difficile Infection Drug Sales by Type (2021-2026) & (k tons) Table 23. Latin America C Difficile Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa C Difficile Infection Drug Sales by Type (2021-2026) & (k tons) Table 25. Middle East and Africa C Difficile Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 26. C Difficile Infection Drug Industry Trends Table 27. C Difficile Infection Drug Industry Drivers Table 28. C Difficile Infection Drug Industry Opportunities and Challenges Table 29. C Difficile Infection Drug Industry Restraints Table 30. Global C Difficile Infection Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global C Difficile Infection Drug Revenue Market Share by Company (2021-2026) Table 32. Global C Difficile Infection Drug Sales by Company (2021-2026) & (k tons) Table 33. Global C Difficile Infection Drug Sales Share by Company (2021-2026) Table 34. Global C Difficile Infection Drug Market Price by Company (2021-2026) & (US$/ton) Table 35. Global C Difficile Infection Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global C Difficile Infection Drug Major Company Production Sites and Headquarters Table 37. Global C Difficile Infection Drug Company, Product Type & Application Table 38. Global C Difficile Infection Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global C Difficile Infection Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global C Difficile Infection Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global C Difficile Infection Drug Sales by Region (2021-2026) & (k tons) Table 43. Global C Difficile Infection Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global C Difficile Infection Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global C Difficile Infection Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global C Difficile Infection Drug Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 47. Global C Difficile Infection Drug Sales by Region (2027-2032) & (k tons) Table 48. Global C Difficile Infection Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global C Difficile Infection Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global C Difficile Infection Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global C Difficile Infection Drug Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2027-2032) Table 52. Global C Difficile Infection Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global C Difficile Infection Drug Sales by Application (2021-2026) & (k tons) Table 54. Global C Difficile Infection Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global C Difficile Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global C Difficile Infection Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global C Difficile Infection Drug Price by Application (2021-2026) & (US$/ton) Table 58. Global C Difficile Infection Drug Sales by Application (2027-2032) & (k tons) Table 59. Global C Difficile Infection Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global C Difficile Infection Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global C Difficile Infection Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global C Difficile Infection Drug Price by Application (2027-2032) & (US$/ton) Table 63. North America C Difficile Infection Drug Sales by Application (2021-2026) & (k tons) Table 64. North America C Difficile Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe C Difficile Infection Drug Sales by Application (2021-2026) & (k tons) Table 66. Europe C Difficile Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific C Difficile Infection Drug Sales by Application (2021-2026) & (k tons) Table 68. Asia-Pacific C Difficile Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America C Difficile Infection Drug Sales by Application (2021-2026) & (k tons) Table 70. Latin America C Difficile Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa C Difficile Infection Drug Sales by Application (2021-2026) & (k tons) Table 72. Middle East and Africa C Difficile Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Zhejiang Medicine Company Information Table 74. Zhejiang Medicine Business Overview Table 75. Zhejiang Medicine C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. Zhejiang Medicine C Difficile Infection Drug Product Portfolio Table 77. Zhejiang Medicine Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 81. Sanofi C Difficile Infection Drug Product Portfolio Table 82. Sanofi Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 86. Merck C Difficile Infection Drug Product Portfolio Table 87. Merck Recent Development Table 88. Eli Lilly Company Information Table 89. Eli Lilly Business Overview Table 90. Eli Lilly C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 91. Eli Lilly C Difficile Infection Drug Product Portfolio Table 92. Eli Lilly Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 96. Pfizer C Difficile Infection Drug Product Portfolio Table 97. Pfizer Recent Development Table 98. Fresenius Company Information Table 99. Fresenius Business Overview Table 100. Fresenius C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 101. Fresenius C Difficile Infection Drug Product Portfolio Table 102. Fresenius Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 106. AstraZeneca C Difficile Infection Drug Product Portfolio Table 107. AstraZeneca Recent Development Table 108. Xellia Company Information Table 109. Xellia Business Overview Table 110. Xellia C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 111. Xellia C Difficile Infection Drug Product Portfolio Table 112. Xellia Recent Development Table 113. Strides Company Information Table 114. Strides Business Overview Table 115. Strides C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 116. Strides C Difficile Infection Drug Product Portfolio Table 117. Strides Recent Development Table 118. Merus labs Company Information Table 119. Merus labs Business Overview Table 120. Merus labs C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 121. Merus labs C Difficile Infection Drug Product Portfolio Table 122. Merus labs Recent Development Table 123. Lupin Company Information Table 124. Lupin Business Overview Table 125. Lupin C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 126. Lupin C Difficile Infection Drug Product Portfolio Table 127. Lupin Recent Development Table 128. Flynn Pharma Company Information Table 129. Flynn Pharma Business Overview Table 130. Flynn Pharma C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 131. Flynn Pharma C Difficile Infection Drug Product Portfolio Table 132. Flynn Pharma Recent Development Table 133. Astellas Company Information Table 134. Astellas Business Overview Table 135. Astellas C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 136. Astellas C Difficile Infection Drug Product Portfolio Table 137. Astellas Recent Development Table 138. Aspen Pharmacare Company Information Table 139. Aspen Pharmacare Business Overview Table 140. Aspen Pharmacare C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 141. Aspen Pharmacare C Difficile Infection Drug Product Portfolio Table 142. Aspen Pharmacare Recent Development Table 143. ANI Pharmaceutical Company Information Table 144. ANI Pharmaceutical Business Overview Table 145. ANI Pharmaceutical C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 146. ANI Pharmaceutical C Difficile Infection Drug Product Portfolio Table 147. ANI Pharmaceutical Recent Development Table 148. Akorn Company Information Table 149. Akorn Business Overview Table 150. Akorn C Difficile Infection Drug Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 151. Akorn C Difficile Infection Drug Product Portfolio Table 152. Akorn Recent Development Table 153. North America C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 154. North America C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 155. North America C Difficile Infection Drug Sales Market Share by Country (2021-2026) Table 156. North America C Difficile Infection Drug Sales Forecast by Country (2027-2032) & (k tons) Table 157. North America C Difficile Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 158. North America C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. North America C Difficile Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 160. North America C Difficile Infection Drug Market Share by Country (2021-2026) Table 161. North America C Difficile Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. North America C Difficile Infection Drug Market Share Forecast by Country (2027-2032) Table 163. Europe C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 164. Europe C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 165. Europe C Difficile Infection Drug Sales Market Share by Country (2021-2026) Table 166. Europe C Difficile Infection Drug Sales Forecast by Country (2027-2032) & (k tons) Table 167. Europe C Difficile Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 168. Europe C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Europe C Difficile Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 170. Europe C Difficile Infection Drug Market Share by Country (2021-2026) Table 171. Europe C Difficile Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Europe C Difficile Infection Drug Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 175. Asia-Pacific C Difficile Infection Drug Sales Market Share by Country (2021-2026) Table 176. Asia-Pacific C Difficile Infection Drug Sales Forecast by Country (2027-2032) & (k tons) Table 177. Asia-Pacific C Difficile Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 178. Asia-Pacific C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Asia-Pacific C Difficile Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 180. Asia-Pacific C Difficile Infection Drug Market Share by Country (2021-2026) Table 181. Asia-Pacific C Difficile Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Asia-Pacific C Difficile Infection Drug Market Share Forecast by Country (2027-2032) Table 183. Latin America C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 184. Latin America C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 185. Latin America C Difficile Infection Drug Sales Market Share by Country (2021-2026) Table 186. Latin America C Difficile Infection Drug Sales Forecast by Country (2027-2032) & (k tons) Table 187. Latin America C Difficile Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 188. Latin America C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Latin America C Difficile Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 190. Latin America C Difficile Infection Drug Market Share by Country (2021-2026) Table 191. Latin America C Difficile Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Latin America C Difficile Infection Drug Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa C Difficile Infection Drug Sales by Country (2021-2026) & (k tons) Table 195. Middle East and Africa C Difficile Infection Drug Sales Market Share by Country (2021-2026) Table 196. Middle East and Africa C Difficile Infection Drug Sales Forecast by Country (2027-2032) & (k tons) Table 197. Middle East and Africa C Difficile Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 198. Middle East and Africa C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Middle East and Africa C Difficile Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 200. Middle East and Africa C Difficile Infection Drug Market Share by Country (2021-2026) Table 201. Middle East and Africa C Difficile Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Middle East and Africa C Difficile Infection Drug Market Share Forecast by Country (2027-2032) Table 203. Key Raw Materials Table 204. Raw Materials Key Suppliers Table 205. C Difficile Infection Drug Distributors List Table 206. C Difficile Infection Drug Customers List Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. C Difficile Infection Drug Image Figure 2. Global C Difficile Infection Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global C Difficile Infection Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global C Difficile Infection Drug Sales (2021-2032) & (k tons) Figure 5. Fidaxomycin Image Figure 6. Global Fidaxomycin Sales YoY Growth (2021-2032) & (k tons) Figure 7. Metronidazole Image Figure 8. Global Metronidazole Sales YoY Growth (2021-2032) & (k tons) Figure 9. Vancomycin Image Figure 10. Global Vancomycin Sales YoY Growth (2021-2032) & (k tons) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k tons) Figure 13. Global C Difficile Infection Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global C Difficile Infection Drug Market Share by Type 2025 VS 2032 Figure 15. North America C Difficile Infection Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America C Difficile Infection Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe C Difficile Infection Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe C Difficile Infection Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific C Difficile Infection Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific C Difficile Infection Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America C Difficile Infection Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America C Difficile Infection Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa C Difficile Infection Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa C Difficile Infection Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 C Difficile Infection Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Pre-treatment Image Figure 28. Global Pre-treatment Sales YoY Growth (2021-2032) & (k tons) Figure 29. Mid-term treatment Image Figure 30. Global Mid-term treatment Sales YoY Growth (2021-2032) & (k tons) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k tons) Figure 33. Global C Difficile Infection Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global C Difficile Infection Drug Market Share by Application 2025 VS 2032 Figure 35. North America C Difficile Infection Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America C Difficile Infection Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe C Difficile Infection Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe C Difficile Infection Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific C Difficile Infection Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific C Difficile Infection Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America C Difficile Infection Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America C Difficile Infection Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa C Difficile Infection Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa C Difficile Infection Drug Sales Market Share in Value by Application in 2025 Figure 45. North America C Difficile Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 46. North America C Difficile Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America C Difficile Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe C Difficile Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 50. Europe C Difficile Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe C Difficile Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific C Difficile Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 54. Asia-Pacific C Difficile Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific C Difficile Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America C Difficile Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 58. Latin America C Difficile Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America C Difficile Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa C Difficile Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 62. Middle East and Africa C Difficile Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa C Difficile Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa C Difficile Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. C Difficile Infection Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. C Difficile Infection Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Fidaxomycin
  • Metronidazole
  • Vancomycin
  • Others
Applications
  • Pre-treatment
  • Mid-term treatment
  • Others
Companies covered
  • Zhejiang Medicine
  • Sanofi
  • Merck
  • Eli Lilly
  • Pfizer
  • Fresenius
  • AstraZeneca
  • Xellia
  • Strides
  • Merus labs
  • Lupin
  • Flynn Pharma
  • Astellas
  • Aspen Pharmacare
  • ANI Pharmaceutical
  • Akorn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global C Difficile Infection Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global C Difficile Infection Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 C Difficile Infection Drug Market by Type
  6. 1.3.1 Fidaxomycin
  7. 1.3.2 Metronidazole
  8. 1.3.3 Vancomycin
  9. 1.3.4 Others
  10. 1.4 Global C Difficile Infection Drug Market Size by Type
  11. 1.4.1 Global C Difficile Infection Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global C Difficile Infection Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global C Difficile Infection Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America C Difficile Infection Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe C Difficile Infection Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific C Difficile Infection Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America C Difficile Infection Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa C Difficile Infection Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 C Difficile Infection Drug Industry Trends
  2. 2.2 C Difficile Infection Drug Industry Drivers
  3. 2.3 C Difficile Infection Drug Industry Opportunities and Challenges
  4. 2.4 C Difficile Infection Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by C Difficile Infection Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by C Difficile Infection Drug Sales (2021-2026)
  3. 3.3 Global Top Players by C Difficile Infection Drug Price (2021-2026)
  4. 3.4 Global C Difficile Infection Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global C Difficile Infection Drug Major Company Production Sites & Headquarters
  6. 3.6 Global C Difficile Infection Drug Company, Product Type & Application
  7. 3.7 Global C Difficile Infection Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global C Difficile Infection Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 C Difficile Infection Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 C Difficile Infection Drug Tier 1, Tier 2, and Tier 3
4 C Difficile Infection Drug Regional Status and Outlook
  1. 4.1 Global C Difficile Infection Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global C Difficile Infection Drug Historic Market Size by Region
  3. 4.2.1 Global C Difficile Infection Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global C Difficile Infection Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global C Difficile Infection Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global C Difficile Infection Drug Forecasted Market Size by Region
  7. 4.3.1 Global C Difficile Infection Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global C Difficile Infection Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global C Difficile Infection Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 C Difficile Infection Drug by Application
  1. 5.1 C Difficile Infection Drug Market by Application
  2. 5.1.1 Pre-treatment
  3. 5.1.2 Mid-term treatment
  4. 5.1.3 Others
  5. 5.2 Global C Difficile Infection Drug Market Size by Application
  6. 5.2.1 Global C Difficile Infection Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global C Difficile Infection Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global C Difficile Infection Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America C Difficile Infection Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe C Difficile Infection Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific C Difficile Infection Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America C Difficile Infection Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa C Difficile Infection Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Zhejiang Medicine
  2. 6.1.1 Zhejiang Medicine Company Information
  3. 6.1.2 Zhejiang Medicine Business Overview
  4. 6.1.3 Zhejiang Medicine C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Zhejiang Medicine C Difficile Infection Drug Product Portfolio
  6. 6.1.5 Zhejiang Medicine Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi C Difficile Infection Drug Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck C Difficile Infection Drug Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Eli Lilly
  20. 6.4.1 Eli Lilly Company Information
  21. 6.4.2 Eli Lilly Business Overview
  22. 6.4.3 Eli Lilly C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly C Difficile Infection Drug Product Portfolio
  24. 6.4.5 Eli Lilly Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer C Difficile Infection Drug Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Fresenius
  32. 6.6.1 Fresenius Company Information
  33. 6.6.2 Fresenius Business Overview
  34. 6.6.3 Fresenius C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Fresenius C Difficile Infection Drug Product Portfolio
  36. 6.6.5 Fresenius Recent Developments
  37. 6.7 AstraZeneca
  38. 6.7.1 AstraZeneca Company Information
  39. 6.7.2 AstraZeneca Business Overview
  40. 6.7.3 AstraZeneca C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 AstraZeneca C Difficile Infection Drug Product Portfolio
  42. 6.7.5 AstraZeneca Recent Developments
  43. 6.8 Xellia
  44. 6.8.1 Xellia Company Information
  45. 6.8.2 Xellia Business Overview
  46. 6.8.3 Xellia C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Xellia C Difficile Infection Drug Product Portfolio
  48. 6.8.5 Xellia Recent Developments
  49. 6.9 Strides
  50. 6.9.1 Strides Company Information
  51. 6.9.2 Strides Business Overview
  52. 6.9.3 Strides C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Strides C Difficile Infection Drug Product Portfolio
  54. 6.9.5 Strides Recent Developments
  55. 6.10 Merus labs
  56. 6.10.1 Merus labs Company Information
  57. 6.10.2 Merus labs Business Overview
  58. 6.10.3 Merus labs C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Merus labs C Difficile Infection Drug Product Portfolio
  60. 6.10.5 Merus labs Recent Developments
  61. 6.11 Lupin
  62. 6.11.1 Lupin Company Information
  63. 6.11.2 Lupin Business Overview
  64. 6.11.3 Lupin C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Lupin C Difficile Infection Drug Product Portfolio
  66. 6.11.5 Lupin Recent Developments
  67. 6.12 Flynn Pharma
  68. 6.12.1 Flynn Pharma Company Information
  69. 6.12.2 Flynn Pharma Business Overview
  70. 6.12.3 Flynn Pharma C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Flynn Pharma C Difficile Infection Drug Product Portfolio
  72. 6.12.5 Flynn Pharma Recent Developments
  73. 6.13 Astellas
  74. 6.13.1 Astellas Company Information
  75. 6.13.2 Astellas Business Overview
  76. 6.13.3 Astellas C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Astellas C Difficile Infection Drug Product Portfolio
  78. 6.13.5 Astellas Recent Developments
  79. 6.14 Aspen Pharmacare
  80. 6.14.1 Aspen Pharmacare Company Information
  81. 6.14.2 Aspen Pharmacare Business Overview
  82. 6.14.3 Aspen Pharmacare C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Aspen Pharmacare C Difficile Infection Drug Product Portfolio
  84. 6.14.5 Aspen Pharmacare Recent Developments
  85. 6.15 ANI Pharmaceutical
  86. 6.15.1 ANI Pharmaceutical Company Information
  87. 6.15.2 ANI Pharmaceutical Business Overview
  88. 6.15.3 ANI Pharmaceutical C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 ANI Pharmaceutical C Difficile Infection Drug Product Portfolio
  90. 6.15.5 ANI Pharmaceutical Recent Developments
  91. 6.16 Akorn
  92. 6.16.1 Akorn Company Information
  93. 6.16.2 Akorn Business Overview
  94. 6.16.3 Akorn C Difficile Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Akorn C Difficile Infection Drug Product Portfolio
  96. 6.16.5 Akorn Recent Developments
7 North America by Country
  1. 7.1 North America C Difficile Infection Drug Sales by Country
  2. 7.1.1 North America C Difficile Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America C Difficile Infection Drug Sales by Country (2021-2026)
  4. 7.1.3 North America C Difficile Infection Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America C Difficile Infection Drug Market Size by Country
  6. 7.2.1 North America C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America C Difficile Infection Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America C Difficile Infection Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe C Difficile Infection Drug Sales by Country
  2. 8.1.1 Europe C Difficile Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe C Difficile Infection Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe C Difficile Infection Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe C Difficile Infection Drug Market Size by Country
  6. 8.2.1 Europe C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe C Difficile Infection Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe C Difficile Infection Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific C Difficile Infection Drug Sales by Country
  2. 9.1.1 Asia-Pacific C Difficile Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific C Difficile Infection Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific C Difficile Infection Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific C Difficile Infection Drug Market Size by Country
  6. 9.2.1 Asia-Pacific C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific C Difficile Infection Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific C Difficile Infection Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America C Difficile Infection Drug Sales by Country
  2. 10.1.1 South America C Difficile Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America C Difficile Infection Drug Sales by Country (2021-2026)
  4. 10.1.3 South America C Difficile Infection Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America C Difficile Infection Drug Market Size by Country
  6. 10.2.1 South America C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America C Difficile Infection Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America C Difficile Infection Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa C Difficile Infection Drug Sales by Country
  2. 11.1.1 Middle East and Africa C Difficile Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa C Difficile Infection Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa C Difficile Infection Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa C Difficile Infection Drug Market Size by Country
  6. 11.2.1 Middle East and Africa C Difficile Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa C Difficile Infection Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa C Difficile Infection Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 C Difficile Infection Drug Value Chain Analysis
  2. 12.1.1 C Difficile Infection Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 C Difficile Infection Drug Production Mode & Process
  7. 12.2 C Difficile Infection Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 C Difficile Infection Drug Distributors
  10. 12.2.3 C Difficile Infection Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst